Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 0.56 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986942 | 0.95 | S1PR1 (0.58) | S1PR1S1PR3USP30HDAC4 | |
| SCHEMBL4746452 | 0.85 | S1PR1 (0.67) | S1PR1S1PR3 | |
| SCHEMBL19746839 | 0.82 | HDAC4 (0.64) | ESR2HDAC4 | |
| SCHEMBL2415343 | 0.81 | S1PR1 (0.68) | S1PR1ESR2USP30 | |
| SCHEMBL2179933 | 0.80 | S1PR1 (0.79) | S1PR1S1PR3 | |
| SCHEMBL2181741 | 0.80 | S1PR1 (0.79) | S1PR1S1PR3 | |
| SCHEMBL2983038 | 0.80 | S1PR1 (0.75) | S1PR1S1PR3 | |
| SCHEMBL2985518 | 0.80 | S1PR1 (0.54) | S1PR1S1PR3HDAC4 | |
| SCHEMBL25574615 | 0.79 | ESR2 (0.58) | ESR2USP30HDAC4 | |
| SCHEMBL10455382 | 0.78 | S1PR1 (0.66) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644367-B1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | NOVARTIS AG (CH) | 2015-10-14 | — | — | EP | disclosed |
| EP-1644367-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2008-12-31 | — | — | EP | disclosed |
| US-7462629-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2008-12-09 | — | — | US | disclosed |
| EP-1644367-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-04-12 | — | — | EP | disclosed |
| US-20050009786-A1 | Immunosuppressant compounds and compositions | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2005-01-13 | — | — | US | disclosed |
| WO-2004113330-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009786-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | S1PR1 133/4885S1PR3 142/4885ESR2 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.